| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTK2 |
| Uniprot No | Q05397 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1052aa |
| 氨基酸序列 | MAAAYLDPNLNHTPNSSTKTHLGTGMERSPGAMERVLKVFHYFESNSEPTTWASIIRHGDATDVRGIIQKIVDSHKVKHVACYGFRLSHLRSEEVHWLHVDMGVSSVREKYELAHPPEEWKYELRIRYLPKGFLNQFTEDKPTLNFFYQQVKSDYMLEIADQVDQEIALKLGCLEIRRSYWEMRGNALEKKSNYEVLEKDVGLKRFFPKSLLDSVKAKTLRKLIQQTFRQFANLNREESILKFFEILSPVYRFDKECFKCALGSSWIISVELAIGPEEGISYLTDKGCNPTHLADFTQVQTIQYSNSEDKDRKGMLQLKIAGAPEPLTVTAPSLTIAENMADLIDGYCRLVNGTSQSFIIRPQKEGERALPSIPKLANSEKQGMRTHAVSVSETDDYAEIIDEEDTYTMPSTRDYEIQRERIELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKLIGVITENPVWIIMELCTLGELRSFLQVRKYSLDLASLILYAYQLSTALAYLESKRFVHRDIAARNVLVSSNDCVKLGDFGLSRYMEDSTYYKASKGKLPIKWMAPESINFRRFTSASDVWMFGVCMWEILMHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTILEEEKAQQEERMRMESRRQATVSWDSGGSDEAPPKPSRPGYPSPRSSEGFYPSPQHMVQTNHYQVSGYPGSHGITAMAGSIYPGQASLLDQTDSWNHRPQEIAMWQPNVEDSTVLDLRGIGQVLPTHLMEERLIRQQQEMEEDQRWLEKEERFLKPDVRLSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPKKPPRPGAPGHLGSLASLSSPADSYNEGVKLQPQEISPPPTANLDRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGLALRTLLATVDETIPLLPASTHREIEMAQKLLNSDLGELINKMKLAQQYVMTSLQQEYKKQMLTAAHALAVDAKNLLDVIDQARLKMLGQTRPH |
| 预测分子量 | 119,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTK2(FAK)重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *"Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src"*
**作者**: Schaller, M.D. et al.
**摘要**: 该研究报道了PTK2(FAK)重组蛋白在昆虫细胞中的表达，证实其自磷酸化活性及与Src激酶的SH2结构域相互作用，揭示了FAK在整合素信号通路中的调控机制。
2. **文献名称**: *"Structural basis for the autoinhibition of focal adhesion kinase"*
**作者**: Lietha, D. et al.
**摘要**: 通过大肠杆菌表达重组人源PTK2激酶结构域蛋白，结合X射线晶体学解析其自抑制构象，阐明了FERM结构域对激酶活性的调控机制。
3. **文献名称**: *"FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication"*
**作者**: Zhang, H. et al.
**摘要**: 利用哺乳动物细胞系表达重组PTK2蛋白，研究其在肿瘤微环境中的功能，证明FAK通过外泌体miRNA调控乳腺癌转移，为靶向治疗提供依据。
---
以上文献涵盖了PTK2重组蛋白的表达、结构解析及功能研究，均发表于《Cell》《Nature》等高水平期刊。建议通过PubMed或Web of Science进一步检索具体细节。
**Background of PTK2 Recombinant Protein**
PTK2 (Protein Tyrosine Kinase 2), also known as Focal Adhesion Kinase (FAK), is a non-receptor tyrosine kinase critical for cellular signaling processes. It plays a central role in regulating cell adhesion, migration, proliferation, and survival by integrating signals from extracellular matrix interactions, growth factor receptors, and mechanosensors. Structurally, PTK2 contains an N-terminal FERM domain, a central kinase domain, and a C-terminal focal adhesion targeting (FAT) domain, which facilitate its localization to focal adhesions and interaction with signaling partners.
Dysregulation of PTK2 is implicated in cancer progression, metastasis, and resistance to therapy, making it a significant therapeutic target. Overexpression or hyperactivation of PTK2 correlates with poor prognosis in various malignancies. To study its function and develop inhibitors, recombinant PTK2 proteins are engineered. These proteins are typically produced using expression systems like *E. coli* or mammalian cells, ensuring proper post-translational modifications (e.g., phosphorylation at key residues like Y397).
Recombinant PTK2 enables *in vitro* kinase assays, structural studies, and drug screening. It also aids in elucidating interactions with binding partners (e.g., Src, paxillin) and downstream pathways (e.g., PI3K/AKT, MAPK). Advances in recombinant technology have improved the yield and activity of PTK2 proteins, supporting both basic research and drug discovery efforts targeting PTK2-associated diseases.
×
